Celldex ( Celldex )

Celldex

Celldex's picture

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.

Celldex press release, blog etc

11/30/2017 - 06:57 Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
11/17/2017 - 07:52 Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
10/03/2017 - 05:58 Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs
09/12/2017 - 11:15 Celldex Announces Departure of Chief Medical Officer
08/23/2017 - 07:40 Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
06/16/2017 - 10:08 Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
06/05/2017 - 10:16 Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma
06/05/2017 - 09:14 Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo at 2017 ASCO Annual Meeting
06/02/2017 - 11:21 Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
03/14/2017 - 13:56 Celldex Provides Corporate Update and Reports Full Year 2016 Results
02/13/2017 - 13:13 Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call
12/14/2016 - 16:12 Celldex Therapeutics Announces Appointment to Board of Directors
12/05/2016 - 14:09 Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team
12/05/2016 - 08:00 Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting
11/29/2016 - 13:29 Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
11/14/2016 - 04:57 Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
11/01/2016 - 14:24 Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals
10/09/2016 - 04:29 Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response